Download PDF
Aktuelle Neurologie 2002; 29(8): 389-401
DOI: 10.1055/s-2002-34965
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Botulinumtoxin in der Schmerztherapie

Botulinum Toxine in the Treatment of PainT.  Probst1 , D.  Dressler1 , R.  Benecke1 , E.  Kunesch1
  • 1Neurologische Klinik und Poliklinik der Universität Rostock
Further Information

Publication History

Publication Date:
23 October 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Botulinumtoxin (BTX) wird seit mehr als 20 Jahren erfolgreich bei Erkrankungen mit muskulären Hyperaktivitäten eingesetzt. In den letzten Jahren kam es zu einer deutlichen Ausweitung der Anwendung bei autonomen Erkrankungen und in der Schmerztherapie. Die analgetischen Wirkungen von BTX-Injektionen werden vor dem Hintergrund erheblicher Plazeboeffekte und teilweise methodischer Mängel der vorgelegten Studien kontrovers diskutiert. Weiterhin bestehen noch unzureichende Konzepte zur Schmerzphysiologie allgemein sowie zu den spezifischen analgetischen Wirkmechanismen von Botulinumtoxin. Neben der Schmerzreduktion durch die bekannte BTX-Wirkung an der neuromuskulären Endplatte werden weitere lokale schmerzreduzierende Mechanismen und Wirkungen an anderen synaptischen Systemen postuliert. Derzeit kann BTX zur Schmerztherapie bei Dystonien und Spastiksyndromen sowie bei Analfissuren und Achalasie empfohlen werden. Bei myofaszialen Schmerzen, Migräne, Kopfschmerzen vom Spannungstyp und anderen seltenen Kopfschmerzsyndromen wurde eine Schmerzreduktion durch BTX berichtet, aber der definitive Beleg nach Kriterien der evidenzbasierten Medizin steht noch aus. Bei Fibromyalgie scheint keine sichere klinische Wirkung vorzuliegen. Es ist zu erwarten, dass in Zukunft die Bedeutung von BTX in der Schmerztherapie zunehmen wird.

Abstract

Botulinum toxin (BTX) has been used for more than 20 years to treat various muscle hyperactivity syndromes. Over the past years its use has expanded into the treatment of autonomic disorders and pain. Analgesic effects of BTX have been discussed controversially due to substantial placebo effects and flaws of the study designs used. Additionally, pathophysiological concepts of pain as well as specific analgesic mechanisms of BTX remain largely unclear. Apart from a pain reduction through the well documented BTX effects at the neuromuscular endplate, additional analgesic mechanisms including other synaptic and local effects have been suggested. Currently, BTX can be recommended for pain treatment in dystonia and spasticity as well as in analfissures and achalasia. In myofascial pain syndromes, migraine, tension-type headache and other rare headache syndromes pain relief by BTX has been reported, but definite proof according to evidence based medicine criteria is still lacking. In fibromyalgia there seems to be no analgesic effect. The role of BTX in pain therapy is likely to increase in the future.

Literatur

  • 1 Scott A B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.  J Pediadr Ophthalmol Strabismus. 1980;  17 21-25
    PubMedGoogle Scholar
  • 2 Aoki K. Pharmacology and immunology of botulinum toxin serotypes.  J Neurol. 2001;  248 (Suppl 1) 3-10
    PubMedGoogle Scholar
  • 3 Dressler D. Botulinum Toxin Therapy. Stuttgart, New York; Thieme 2000
    Google Scholar
  • 4 Jost W, Kohl A. Botulinum toxin: evidence-based medicine criteria in rare indications.  J Neurol. 2001;  248 (Suppl 1) 39-44
    CrossrefPubMedGoogle Scholar
  • 5 Brin M F, Fahn S, Moskowitz C. et al . Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.  Adv Neurol. 1988;  50 599-608
    PubMedGoogle Scholar
  • 6 Brin M F, Lew M, Adler C. et al . Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.  Neurology. 1999;  53 1431-1438
    CrossrefPubMedGoogle Scholar
  • 7 Hilker R, Schischniaschvili M, Ghaemi M. et al . Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.  J Neurol Neurosurg Psychiatry. 2001;  71 193-199
    CrossrefPubMedGoogle Scholar
  • 8 Kelm S, Gerats G, Chalkiadaki A, Hefter H. Reduction of pain and muscle spasms by botulinum toxin A.  Nervenarzt. 2001;  72 302-306
    CrossrefPubMedGoogle Scholar
  • 9 Lew M F, Adornato B T, Duane D D. et al . Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.  Neurology. 1997;  49 701-707
    CrossrefPubMedGoogle Scholar
  • 10 Poewe W, Deuschl G, Nebe A. et al . What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled dose ranging study using dysport.  J Neurol Neurosurg Psychiatry. 1998;  64 13-17
    CrossrefPubMedGoogle Scholar
  • 11 Tarsy D, First E R. Painful cervical dystonia: clinical features and response to treatment with botulinum toxin.  Mov Disord. 1999;  14 1043-1045
    CrossrefPubMedGoogle Scholar
  • 12 Chalkiadaki A, Rohr U P, Hefter H. Frühe Schmerzreduktion in der Therapie von Spastik nach einmaliger Botulinustoxin-A-Injektion.  Dtsch Med Wochenschr. 2001;  126 1361-1364
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Carruthers J, Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin.  J Dermatol Surg Oncol. 1992;  18 17-21
    CrossrefPubMedGoogle Scholar
  • 14 Carruthers A, Langtry J A, Carruthers J, Robinson G. Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections.  Headache. 1999;  39 662-665
    CrossrefPubMedGoogle Scholar
  • 15 Krack P, Hornig C, Dorndorf W. Resolution of chronic tension-type headache after botulinum toxin treatment of idiopathic blepharospasm.  Mov Disord. 1995;  10 388
    PubMedGoogle Scholar
  • 16 Mense S. Neurobiologische Grundlagen von Muskelschmerz.  Schmerz. 1999;  13 3-17
    CrossrefPubMedGoogle Scholar
  • 17 Simons D G, Mense S. Understanding and measurement of muscle tone as related to clinical muscle pain.  Pain. 1998;  75 1-17
    CrossrefPubMedGoogle Scholar
  • 18 Porta M, Perretti A, Gamba M, Luccarelli G, Fornari M. The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A.  Pain Digest. 1998;  8 346-352
    PubMedGoogle Scholar
  • 19 Cui M L, Khanijou S, Rubino J, Aoki K R. Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. New Orleans; Society for Neuroscience Annual Meeting 2000 Poster 246.2
    Google Scholar
  • 20 Dolly J, Ashton A, Evans D. et al .Molecular action of botulinum neurotoxins: role of acceptors in targetting to cholinergic nerves and in the inhibition of the release of several transmitters. In: Dowdall M, Hawthorne J (eds) Cellular and molecular basis of cholinergic function. Chichester; Ellis Horwood 1987: 517-535
    Google Scholar
  • 21 Puffer E, Lomneth R, Sarkar H, Singh B. Differential roles of developmentally distinct SNAP-25 isoforms in the neurotransmitter release process.  Biochemistry. 2001;  40 9374-9378
    CrossrefPubMedGoogle Scholar
  • 22 Sala C, Adreose J, Fumagalli G. et al . Calcitonin gene-related peptide: possible role in formation and maintenance of neuromuscular junctions.  J Neurosci. 1995;  15 520-528
    PubMedGoogle Scholar
  • 23 Suzuki N, Hardebo J E, Kahrstrom J. et al . Neuropeptide Y co-exists with vasoactive intestinal polypeptide and acetylcholine in parasympathetic cerebrovascular nerves originating in the sphenopalatine, otic and internal carotid ganglia of the rat.  Neuroscience. 1990;  36 507-519
    PubMedGoogle Scholar
  • 24 Welch M, Purkiss J, Foster K. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.  Toxicon. 2000;  38 245-258
    CrossrefPubMedGoogle Scholar
  • 25 Ferrari M. Migraine.  Lancet. 1998;  351 1043-1051
    CrossrefPubMedGoogle Scholar
  • 26 Binder W J, Brin M F, Blitzer A. et al . Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.  Otolaryngol Head Neck Surg. 2000;  123 669-676
    CrossrefPubMedGoogle Scholar
  • 27 Aoki K, Weber J, Patten P. et al .United States Patent Number 6 113 915,. Sep. 5, 2000
    Google Scholar
  • 28 Wiegand H, Erdmann G, Wellhöner H H. 125 I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection.  Naunyn Schmiedeberg's Arch Pharmacol. 1976;  292 161-165
    CrossrefPubMedGoogle Scholar
  • 29 Hagenah R, Benecke R, Wiegand H. Effects of type A Botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurones.  Naunyn Schmiedeberg's Arch Pharmacol. 1977;  299 267-272
    PubMedGoogle Scholar
  • 30 Filippi G M, Errico P, Santarelli R. et al . Botulinum A toxin effects on rat jaw muscle spindles.  Acta Otolaryngol. 1993;  113 400-404
    CrossrefPubMedGoogle Scholar
  • 31 Rosales R L, Arimura K, Ikenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection.  Muscle Nerve. 1996;  19 488-496
    PubMedGoogle Scholar
  • 32 Guyer B M. Mechanism of botulinum toxin in the relief of chronic pain.  Curr Rev Pain. 1999;  3 427-431
    PubMedGoogle Scholar
  • 33 Humm A, Pabst C, Lauterburg T, Burgunder J. Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin.  Exp Neurol. 2000;  161 361-372
    CrossrefPubMedGoogle Scholar
  • 34 Priori A, Berardelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles.  Brain. 1995;  118 801-807
    PubMedGoogle Scholar
  • 35 Ärztliche Zentralstelle für Qualitätssicherung .Leitlinien-Info. ÄZQ-Schriftenreihe, Band 1. München; Zuckerschwerdt 1999: 62-68
    Google Scholar
  • 36 Scottish intercollegiate guidelines network .SIGN Guidelines - An introduction to SIGN Methodology for the development of evidence-based clinical guidelines. Edinburgh; SIGN Publication Number 39. SIGN Secretariat. Royal College of Physicians 1999
    Google Scholar
  • 37 Chan J, Brin M, Fahn S. Idiopathic cervical dystonia: clinical characteristics.  Mov Disord. 1991;  6 119-126
    CrossrefPubMedGoogle Scholar
  • 38 Lindeboom R, Brans J, Aramideh M. et al . Treatment of cervical dystonia: A comparison of outcome measures for outcome assessment.  Mov Disord. 1998;  13 706-712
    CrossrefPubMedGoogle Scholar
  • 39 Pal P K, Samii A, Schulzer M. et al . Head tremor in cervical dystonia.  Can J Neurol Sci. 2000;  27 137-142
    PubMedGoogle Scholar
  • 40 Behari M. Botulinum toxin in the treatment of writer's cramp.  J Assoc Physicians India. 1999;  47 694-698
    PubMedGoogle Scholar
  • 41 Kunig G, Pogarell O, Oertel W H. Facial pain in a case of cranial dystonia: a case report.  Cephalagia. 1998;  18 709-711
    CrossrefPubMedGoogle Scholar
  • 42 Comella C, Shannon K, Jaglin J. Extensor truncal dystonia: Successful treatment with botulinum toxin injections.  Mov Disord. 1998;  13 552-555
    CrossrefPubMedGoogle Scholar
  • 43 Cordiviari C, Misra V, Catania S, Lees A. Treatment of dystonic clenched fist with botulinum toxin.  Mov Disord. 2001;  16 907-913
    CrossrefPubMedGoogle Scholar
  • 44 Pacchetti C, Albani G, Martignoni E. et al . „Off” painful dystonia in Parkinson's disease treated with botulinum toxin.  Mov Disord. 1995;  10 333-336
    CrossrefPubMedGoogle Scholar
  • 45 Dressler D, Argyrakis A, Schönle P W. et al . Botulinumtoxintherapie in der Rehabilitationsneurologie.  Nervenarzt. 1996;  67 686-694
    CrossrefPubMedGoogle Scholar
  • 46 Reichel G. Botulinum toxin for treatment of spasticity in adults.  J Neurol. 2001;  248 (Suppl 1) 25-27
    PubMedGoogle Scholar
  • 47 Benecke R. Botulinum toxin treatment in spasticity of lower extremities. In: Jankovic J, Hallet M (eds) Therapy with Botulinum Toxin. New York; Marcel Dekker 1994: 463-473
    Google Scholar
  • 48 Bhakta B, Cozens J A, Bamford J M, Chamberlain M A. Use of botulinum toxin in stroke patients with severe upper limb spasticity.  J Neurol Neurosurg Psychiatry. 1996;  61 30-35
    PubMedGoogle Scholar
  • 49 Dunne J W, Heye N, Dunne S L. Treatment of chronic limb spasticity with botulinum toxin.  J Neurol Neurosurg Psychiatry. 1995;  58 232-235
    PubMedGoogle Scholar
  • 50 Pierson S H, Katz D I, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications and patient selection.  Arch Phys Med Rehabil. 1996;  77 717-721
    CrossrefPubMedGoogle Scholar
  • 51 Wissel J, Muller J, Dressnandt J. et al . Management of spasticity associated pain with botulinum toxin A.  J Pain Symptom Manage. 2000;  20 44-49
    CrossrefPubMedGoogle Scholar
  • 52 Barwood S, Baillieu C, Boyd R. et al . Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial.  Dev Med Child Neurol. 2000;  42 116-121
    CrossrefPubMedGoogle Scholar
  • 53 Grazko M A, Polo K B, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity.  Neurology. 1995;  45 712-717
    PubMedGoogle Scholar
  • 54 Bakheit A M, Pittstock S, Moore A P. et al . A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke.  Eur J Neurol. 2001;  8 559-565
    CrossrefPubMedGoogle Scholar
  • 55 Bhakta B, Cozens J A, Chamberlain M A, Bamford J M. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomized double-blind placebo controlled trial.  J Neurol Neurosurg Psychiatry. 2000;  69 217-221
    CrossrefPubMedGoogle Scholar
  • 56 Hyman N, Barnes M, Bhakta B. et al . Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, placebo-controlled, dose ranging study.  J Neurol Neurosurg Psychiatry. 2000;  68 707-712
    CrossrefPubMedGoogle Scholar
  • 57 Hong C, Simons D. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points.  Arch Phys Med Rehabil. 1998;  79 863-872
    CrossrefPubMedGoogle Scholar
  • 58 Hubbard D, Berkoff G. Myofascial trigger points show spontaneous needle EMG activity.  Spine. 1993;  18 1803-1807
    CrossrefPubMedGoogle Scholar
  • 59 Acquadro M A, Borodic G E. Treatment of myofascial pain with botulinum A toxin.  Anesthesiology. 1994;  80 705-706
    PubMedGoogle Scholar
  • 60 Cheshire W P, Abashian S W, Mann J D. Botulinum toxin in the treatment of myofascial pain syndrome.  Pain. 1994;  59 65-69
    CrossrefPubMedGoogle Scholar
  • 61 Yue S K. Initial experience in the use of botulinum-toxin A for the treatment of myofascial related muscle dysfunctions.  J Musculoscelet Pain. 1995;  3 (Suppl 1) 22
    PubMedGoogle Scholar
  • 62 Monsivais J J, Monsivais D B. Botulinum toxin in painful syndromes.  Hand Clin. 1996;  12 787-789
    PubMedGoogle Scholar
  • 63 Alo K M, Yland M J, Kramer D L. et al . Botulinum toxin in the treatment of myofascial pain.  The Pain Clinic. 1997;  10 107-116
    PubMedGoogle Scholar
  • 64 Galate J F, Childers M K, Gnatz S. Effectiveness of botulinum toxin in refractory piriformis muscle syndrome.  Arch Phys Med Rehabil. 1997;  78 1041
    PubMedGoogle Scholar
  • 65 Wheeler A H, Goolkasian P, Gretz S S. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome.  Spine. 1998;  23 1662-1666
    CrossrefPubMedGoogle Scholar
  • 66 Diaz J H, Gould H J. Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin.  Anesthesiology. 1999;  91 877-899
    PubMedGoogle Scholar
  • 67 Jordan S E, Ahn S S, Freischlag J A. et al . Selective botulinum chemodenervation of the scalene muscles for treatment of neurogenic thoracic outlet syndrome.  Ann Vasc Surg. 2000;  14 365-369
    CrossrefPubMedGoogle Scholar
  • 68 Lutze M A. CT-gestützte Injektionen von Botulinumtoxin A beim myofaszialen Schmerzsyndrom.  Schmerz. 2000;  Suppl 1 91
    PubMedGoogle Scholar
  • 69 Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm.  Pain. 2000;  85 101-105
    CrossrefPubMedGoogle Scholar
  • 70 Nouwen A, Bush C. The relationship between paraspinal EMG and chronic low back pain.  Pain. 1984;  20 109-123
    CrossrefPubMedGoogle Scholar
  • 71 Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study.  Neurology. 2001;  56 1290-1293
    CrossrefPubMedGoogle Scholar
  • 72 Paulson G W, Gill W. Botulinum toxin is unsatisfactory therapy for fibromyalgia.  Mov Disord. 1996;  11 459
    CrossrefPubMedGoogle Scholar
  • 73 Asherson R A, Pascoe L. The use of botulinum toxin-A in the treatment of patients with fibromyalgia.  J Rheumatol. 2001;  28 1740
    PubMedGoogle Scholar
  • 74 Göbel H, Petersen-Braun M, Soyka D. The epidemiology of headache in Germany: A nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society.  Cephalalgia. 1994;  14 97-106
    CrossrefPubMedGoogle Scholar
  • 75 Jensen R. Pathophysiological mechanisms of tension-type headache: a review of epidemiological and experimental studies.  Cephalalgia. 1999;  19 602-621
    CrossrefPubMedGoogle Scholar
  • 76 Jensen R, Olesen J. Tension-type headache: an update on mechanisms and treatment.  Curr Opin Neurol. 2000;  13 285-289
    CrossrefPubMedGoogle Scholar
  • 77 Olesen J. Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs.  Pain. 1991;  46 125-132
    CrossrefPubMedGoogle Scholar
  • 78 Pikoff H. Is the muscular model of headache still viable? A review of conflicting data.  Headache. 1984;  24 186-198
    CrossrefPubMedGoogle Scholar
  • 79 Zwart J A, Bovim G, Sand T, Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles.  Headache. 1994;  34 458-462
    CrossrefPubMedGoogle Scholar
  • 80 Relja M A, Korsic M. Treatment of tension-type headache by local injection of botulinum toxin.  Eur J Neurol. 1997;  4 (Suppl 2) 71-73
    PubMedGoogle Scholar
  • 81 Wheeler A H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension.  Headache. 1998;  38 468-471
    CrossrefPubMedGoogle Scholar
  • 82 Göbel H, Lindner V, Krack P. et al . Treatment of chronic tension-type headache with botulinum toxin.  Cephalalgia. 1999;  19 455
    PubMedGoogle Scholar
  • 83 Schulte-Mattler W J, Wieser T, Zierz S. Treatment of tension-type headache with botulinum toxin: a pilot study.  Eur J Med Res. 1999;  4 183-186
    PubMedGoogle Scholar
  • 84 Relja M A, Korsic M. Treatment of tension-type headache by injections with botulinum toxin type A: a double-blind placebo-controlled study.  Neurology. 1999;  52 (Suppl 2) 203
    PubMedGoogle Scholar
  • 85 Smuts J A, Baker M K, Smuts H M. Botulinum toxin type A as prophylactic treatment in chronic tension-type headache.  Cephalalgia. 1999;  19 454
    PubMedGoogle Scholar
  • 86 Porta M. A comparative trial of botulinum toxin A and methylprednisolone for the treatment of tension-type headache.  Curr Rev Pain. 2000;  4 31-35
    PubMedGoogle Scholar
  • 87 Relja M A. Treatment of tension-type headache with botulinum toxin: 1-year-follow-up.  Cephalalgia. 2000;  20 336
    PubMedGoogle Scholar
  • 88 Rollnik J D, Tanneberger O, Schubert M. et al . Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study.  Headache. 2000;  40 300-305
    CrossrefPubMedGoogle Scholar
  • 89 Wollina U. Botulinum A toxin for wrinkles: release from tension headache.  J Eur Acad Dermatol Venereol. 2000;  14 142-143
    PubMedGoogle Scholar
  • 90 Schmitt W J, Slowey E, Fravi N. et al . Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial.  Headache. 2001;  41 658-664
    CrossrefPubMedGoogle Scholar
  • 91 Diener H C, Brune K, Gerber W. et al . Behandlung der Migräneattacke und Migräneprophylaxe.  Dtsch Ärztebl. 1997;  94 3092-3102
    PubMedGoogle Scholar
  • 92 Nelson C F. The tension headache, migraine headache continuum: a hypothesis.  J Manipulative Physiol Ther. 1994;  17 156-167
    PubMedGoogle Scholar
  • 93 Brin M F, Swope D M, O'Brien C. et al . Botox® for migraine: double-blind, placebo-controlled, region-specific evaluation.  Cephalalgia. 2000;  20 421-422
    CrossrefPubMedGoogle Scholar
  • 94 Mauskop A, Basdeo R. Botulinum toxin A is an effect prophylactic therapy of migraines.  Cephalalgia. 2000;  20 422
    PubMedGoogle Scholar
  • 95 Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.  Headache. 2000;  40 445-450
    CrossrefPubMedGoogle Scholar
  • 96 Smuts J A, Barnard P WA. Botulinum toxin type A in the treatment of headache syndromes: a clinical report of 79 patients.  Cephalalgia. 2000;  20 332
    CrossrefPubMedGoogle Scholar
  • 97 Klapper J A, Mathew N T, Klapper A, Kailasam J. Botulinum toxin type A (BTX-A) for the prophylaxis of chronic daily headache.  Cephalalgia. 2000;  20 291-292
    CrossrefPubMedGoogle Scholar
  • 98 Harris M, Feinmann C, Wise M, Treasure F. Temporomandibular joint and orofacial pain: clinical and medicolegal management problems.  Br Dent J. 1993;  174 129-136
    CrossrefPubMedGoogle Scholar
  • 99 Headache classification committee of the international headache society . Classification and diagnosis criteria for headache disorders, cranial neuralgia and facial pain.  Cephalalgia. 1988;  8 (Suppl 7) 1-92
    CrossrefPubMedGoogle Scholar
  • 100 Ginies P R, Fraimout J L, Kong A. et al .Treatment of cluster headache by subcutaneous injection of botulinum toxin. 8. World Congress on Pain 1996 Poster presentation: 50
    Google Scholar
  • 101 Freund B J, Schwartz M. The use of Botulinum toxin A in the treatment of refractory cluster headache: case reports.  Cephalalgia. 2000;  20 329-330
    PubMedGoogle Scholar
  • 102 Girdler N M. Use of botulinum toxin to alleviate facial pain (letter).  Brit J Hospital Med. 1994;  52 362-363
    PubMedGoogle Scholar
  • 103 Finn S, Ryan P, Sleeman D. The medical management of masseteric hypertrophy with botulinum toxin.  J Ir Dent Assoc. 2000;  46 84-86
    PubMedGoogle Scholar
  • 104 Freund B, Schwartz M, Symington J M. Botulinum toxin: new treatment for temporomandibular disorders.  Br J Oral Maxillofac Surg. 2000;  38 466-471
    CrossrefPubMedGoogle Scholar
  • 105 von Lindern J. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction.  Acta Neurol Belg. 2001;  101 39-41
    PubMedGoogle Scholar
  • 106 Hobson D E, Gladish D F. Botulinum toxin injection for cervicogenic headache.  Headache. 1997;  37 253-255
    CrossrefPubMedGoogle Scholar
  • 107 Freund B J, Schwartz M. Treatment of whiplash associated neck pain with botulinum toxin-A: report of 8 cases.  J Rheumatol. 1999;  26 756-758
    PubMedGoogle Scholar
  • 108 Freund B J, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study.  Headache. 2000;  40 231-236
    CrossrefPubMedGoogle Scholar
  • 109 Pollmann W, Keidel M, Pfaffenrath V. Headache and the cervical spine: a critical review.  Cephalalgia. 1997;  17 801-816
    CrossrefPubMedGoogle Scholar
  • 110 Hoogerwerf W A, Pasricha P J. Botulinum toxin for spastic gastrointestinal disorders.  Baillieres Best Pract Res Clin Gastroenterol. 1999;  13 131-143
    CrossrefPubMedGoogle Scholar
  • 111 Cuillere C, Ductrotte P, Zerbib F. et al . Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin.  Gut. 1997;  41 87-92
    PubMedGoogle Scholar
  • 112 Pasricha P J, Ravich W J, Hendrix T R. et al . Intrasphincteric botulinum toxin for the treatment of achalasia.  N Engl J Med. 1995;  322 774-778
    PubMedGoogle Scholar
  • 113 Pasricha P J, Miskovsky E P, Kalloo A N. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction.  Gut. 1994;  35 1319-1321
    PubMedGoogle Scholar
  • 114 Sherman S, Kopecky K K, Brashear A, Lehmann G A. Percutaneus celiac plexus block with botulinum toxin A did not help the pain of chronic pancreatitis.  J Clin Gastroenterol. 1995;  20 343-344
    PubMedGoogle Scholar
  • 115 Wehrmann T, Seifert H, Seipp M. et al . Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction.  Endoscopy. 1998;  30 702-707
    PubMedGoogle Scholar
  • 116 Muehldorfer S, Hahn E. Botulinum toxin injection as a diagnostic tool for verification of Oddi dysfunction causing recurrent pancreatitis.  Endoscopy. 1997;  29 120-124
    PubMedGoogle Scholar
  • 117 Brisinda G, Maria G, Bentivoglio A R. et al . A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure.  N Engl J Med. 1999;  341 65-69
    CrossrefPubMedGoogle Scholar
  • 118 Jost W. One hundred cases of anal fissure treatmed with botulin toxin: early and long-term results.  Dis Colon Rectum. 1997;  40 1029-1032
    CrossrefPubMedGoogle Scholar
  • 119 Maria G, Cassetta E, Gui D. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure.  N Engl J Med. 1998;  338 217-220
    CrossrefPubMedGoogle Scholar
  • 120 Christiansen J, Bruun E, Skjoldbye B, Hagen K. Chronic idiopathic anal pain: analysis of ultrasonography, pathology, and treatment.  Dis Colon Rectum. 2001;  44 661-665
    PubMedGoogle Scholar
  • 121 Zermann D, Ishigoka M, Schubert J, Schmidt R. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain?.  Eur Urol. 2000;  38 393-399
    CrossrefPubMedGoogle Scholar

Dr. med. T. Probst
Prof. Dr. med. E. Kunesch

Klinik für Neurologie und Poliklinik Universität Rostock

Gehlsheimer Straße 20

18147 Rostock

Email: thomas.probst@med.uni-rostock.de

Email: erwin.kunesch@med.uni-rostock.de

      >